Insulinoma

Orphan designation: Ersodetug Treatment of insulinoma, 12/01/2024 Positive

Retrieved on: 
Thursday, April 18, 2024
Patient, Committee, EMA, IRIS, COMP, European Commission, Marketing, Insulinoma, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of insulinoma on 12 January 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Lilly to Divest BAQSIMI to Amphastar

Retrieved on: 
Monday, April 24, 2023
CIBC Bank USA, AMPH, P.C, Insulin, JPMorgan Chase, Covington & Burling, Gland, Diabetes, Kirkland & Ellis, Marketing, Neoplasm, Cathay Bank, Glucagon, Pancreas, Wilson Sonsini Goodrich & Rosati, GAAP, Obesity, Wilson, Capital One, Eli Lilly, Wells Fargo, LLY, Jefferies Group, Hypoglycemia, Acquisition, Allergy, Patient, Insulinoma, Pheochromocytoma, J. P. Morgan, Growth, NYSE, Fifth Third Bank, Eli Lilly and Company, Pharmaceutical industry, Bank, Amphastar Pharmaceuticals, Lilly

INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

Key Points: 
  • INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
  • Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
  • Lilly launched BAQSIMI in 2019 as an option to quickly render aid in rescue situations for people with diabetes who take insulin and it is currently available in 27 international markets.
  • Each of Lilly and Amphastar will determine their applicable accounting treatment for this transaction according to Generally Accepted Accounting Principles (GAAP) upon closing.

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

Retrieved on: 
Wednesday, March 16, 2022
Other Consumer, Medical Supplies, Women, Diabetes, Men, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Neurology, Twitter, Bulla, Glucagon, Anaphylaxis, Face, Blood pressure, Patient, Acid erosion, Necrolytic migratory erythema, U.S. Securities and Exchange Commission, NME, Excipient, Starvation, Adrenal insufficiency, Annual report, Private Securities Litigation Reform Act, Regulation, Breathe Me, Kit, FDA, Nasdaq, Risk, COVID-19, Perineum, Hypersensitivity, Catecholamine, Hypoglycemia, Disclosure, PFS, Vomiting, Security (finance), Glucose, Adult, Allergy, Neoplasm, Pulse, Pheochromocytoma, Endocrinology, Scaly, Nausea, Insulin, Company, Insulinoma, Regulation Fair Disclosure, Groin, Instagram, View, Hypotension, Indometacin, Gastroenterology, Blood, Warfarin, LinkedIn, Diabetes, Pharmaceutical industry, Dentistry, Medical imaging

Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

Key Points: 
  • Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
  • In August 2021, the FDA approved Gvoke Kit, the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.
  • GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.
  • GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency

Retrieved on: 
Saturday, September 25, 2021
Online, Degenerative disease, BRC, Food, Dizziness, Tremor, Completeness, LLY, Neoplasm, Exocrine gland, Hunger, Tongue, Blood pressure, Pulse, Compliance, Quarantine, Somnolence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fax, Lactose, Extrapyramidal system, Sleep, FDA, Patient, Grammatical mood, Allergy, Adult, Insulinoma, Glucagonoma, Radical behaviorism, Pheochromocytoma, Restless, Paresthesia, Irritability, Expiration, Personality, Diabetes, Interactivity, Freepost, Death, Perspiration, Knowledge, Lightheadedness, Confusion, Headache, Injection, Nerve, Pancreas, Hypoglycemia, Safety, Consciousness, NYSE, Anxiety, Seizure, Sedgwick, Pharmaceutical industry, Dietary supplement, Medical imaging, Liquor

The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.

Key Points: 
  • The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
  • Glucagon Emergency Kit is used as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus.
  • The affected Glucagon Emergency Kit lot is D239382D and the expiration date is April 2022 (label expiry date: 04 2022).
  • Wholesalers and Distributors with an existing inventory of Glucagon Emergency Kit lot D239382D should cease distribution and quarantine the product immediately.

Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

Retrieved on: 
Tuesday, September 10, 2019
FDA, Health, Diabetes, Clinical trials, Pharmaceutical, Endocrine system, Organ systems, Endocrine diseases, Eli Lilly and Company, RTT, Glucagon, Insulinoma, Pheochromocytoma, Hypoglycemia, Insulin, Severe Hypoglycemia, Glucagon, Xeris Pharmaceuticals, Inc.

GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and patients with a known hypersensitivity to glucagon or to any of the excipients in GVOKE.

Key Points: 
  • GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and patients with a known hypersensitivity to glucagon or to any of the excipients in GVOKE.
  • Usability research evaluating the GVOKE PFS and GVOKE HypoPen demonstrated nearly 100% success rates in administering a full dose of glucagon using the simple 2-step administration process.
  • GVOKE is indicated for the treatment of severe hypoglycemia in patients with diabetes ages 2 years and above.
  • GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in GVOKE.

The insulinoma treatment market will register a CAGR of over 4% by 2023

Retrieved on: 
Wednesday, January 23, 2019
Medicine, Cancer, Endocrine system, Insulinoma, Pancreatic cancer, Endocrine oncology, Neuroendocrine tumor, Laparoscopy, Insulin

Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market.

Key Points: 
  • Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market.
  • Technavio's analysts have predicted that the insulinoma treatment market will register a CAGR of over 4% by 2023.
  • Therefore, such advance in the field of diagnosis of neuroendocrine tumors will have a positive impact on the global insulinoma treatment market.
  • The global insulinoma treatment market is moderately concentrated, and as the market is in a growth phase, the competition is intense.

Global Insulinoma Treatment Market Analysis & Outlook 2019-2023; Led by Ipsen Pharma, Johnson & Johnson, Novartis, Pfizer, and Teva Pharmaceutical Industries - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 23, 2019
Health, Oncology, Pharmaceutical, Medicine, Clinical medicine, Insulinoma, Laparoscopy, Medical diagnosis

The "Global Insulinoma Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Insulinoma Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The insulinoma treatment market will register a CAGR of over 4% by 2023.
  • Advances in laparoscopic treatment and diagnostic techniques have a considerable impact on the global insulinoma treatment market.
  • Therefore, such advance in the field of diagnosis of neuroendocrine tumors will have a positive impact on the global insulinoma treatment market.

Global Insulinoma Treatment Market 2019-2023 | Strategic Alliances to Drive Growth | Technavio

Retrieved on: 
Wednesday, January 9, 2019
Surgery, Health, Medical devices, Oncology, Pharmaceutical, Insulinoma, Market research

Technavio analysts forecast the global insulinoma treatment market to grow at a CAGR of over 3% during the forecast period, according to their latest market research report.

Key Points: 
  • Technavio analysts forecast the global insulinoma treatment market to grow at a CAGR of over 3% during the forecast period, according to their latest market research report.
  • View the full release here: https://www.businesswire.com/news/home/20190109005294/en/
    Technavio has published a new market research report on the global insulinoma treatment market from 2019-2023.
  • (Graphic: Business Wire)
    Strategic alliances are one of the major trends being witnessed in the global insulinoma treatment market 2019-2023 .
  • The global insulinoma treatment market research report provides market segmentation by type (surgery, drugs, and other treatments) and by region (the Americas, EMEA, and APAC).